Gilead Sciences’ (GILD) total HIV sales got a boost from the US market. The HIV product sales in the United States increased from $2.52 billion in the third quarter of 2017 to $3.0 billion in the third quarter. The HIV product sales in Europe decreased from $656.0 million in the third quarter of 2017 to $584.0 million in the third quarter. The sales in other international markets decreased from $156.0 million in the third quarter of 2017 to $138.0 million in the third quarter. Gilead Sciences’ Biktarvy generated US sales of $375.0 million in the third quarter, which was the second full quarter of sales for the product.
Stock price performance
Gilead Sciences stock corrected from $88.80 on January 29 to $64.88 on May 7. The stock recovered to $79.0 on October 3.
Amid the broader market turmoil in October, Gilead Sciences stock witnessed selling pressure and fell to $68.18 on October 31. Currently, the stock is trading at $70 levels in November.
Gilead Sciences’ enterprise value is $94.93 billion. The company’s enterprise value-to-revenue ratio is 4.09. The stock is trading at a forward PE multiple of 10.39x. Gilead Sciences price-to-sales ratio is 3.93, while the price-to-book value ratio is 4.21. In comparison, Bristol-Myers Squibb (BMY), Merck (MRK), and Pfizer’s (PFE) price-to-book value ratios are 6.24, 6.03, and 3.67, respectively.
Next, we’ll discuss analysts’ views on Gilead Sciences stock.